Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile-associated Diarrhea (CDAD)
Conditions
Clostridium Difficile-associated Diarrhea (CDAD)
Trial Timeline
Jan 9, 2015 → Mar 7, 2018
NCT ID
NCT02218372About Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules is a phase 3 stage product being developed by Astellas Pharma for Clostridium Difficile-associated Diarrhea (CDAD). The current trial status is completed. This product is registered under clinical trial identifier NCT02218372. Target conditions include Clostridium Difficile-associated Diarrhea (CDAD).
What happened to similar drugs?
9 of 20 similar drugs in Clostridium Difficile-associated Diarrhea (CDAD) were approved
Approved (9) Terminated (5) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02218372 | Phase 3 | Completed |
Competing Products
20 competing products in Clostridium Difficile-associated Diarrhea (CDAD)